Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Osmotic Bolus Injector Reduces Injection Frequency

By HospiMedica International staff writers
Posted on 28 Jul 2021
A novel osmotic drive powers low-cost bolus injection technology that can be applied to a broad range of drugs.

The Subcuject (Hellebaek, Denmark) Osmotic Wearable Bolus Injector (WBI) is a low-cost, patient-friendly, prefilled bolus injector that utilizes forward osmosis technology to deliver three ml of a fluid drug of choice. More...
In simplified terms, the osmotic drive module contains two chambers of liquid separated by a semipermeable membrane. Controlled addition of salt to one chamber draws in liquid from the other chamber, generating hydraulic/mechanical pressure that drives the plunger in the primary drug container.

Feature of the single use, disposable WBI device include invisible, automatic thin needle insertion and retraction; small size (76 mm) and low weight 55 grams); thin needles; and noiseless operation, as there are no electronics or batteries involved. To activate the Osmotic WBI, it is affixed to the skin, activated by a single button press, and discarded after use. Total injection time is between 245 and 349 seconds, depending on the viscosity of the drug and needle gauge. No assembly is required, and there are no settings to be adjusted.

“Subcuject has developed a purely mechanical wearable injector for single use, using forward osmosis as the drive mechanism and using a standard glass primary container. This achieves significant economic advantage, with the device cost expected to be in the range of a single-use autoinjector,” said Claus Schmidt Moeller, CTO of Subcuject. “As pressure needs to be built up before the plunger starts moving, there is a soft injection start for increased patient comfort and minimized risk of impact damage in the primary container.”

Osmosis is a spontaneous process, where water molecules cross a membrane in both directions without spending any external energy (Brownian movements). When an osmotic agent (such as salt) is dissolved in the water on one side of the membrane, each ion of a dissolved salt crystal attracts and binds several water molecules. The permeability of these hydrated ions through the membrane is much lower than for the free water molecules, and they stay on one side of the membrane due to a combination of their size and the complex hydrophilic/hydrophobic properties of the membrane. This results in spontaneous flow of water molecules from the freshwater side to the saltwater side of the membrane, building up pressure.

Related Links:
Subcuject


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Radiation Safety Barrier
RayShield Intensi-Barrier
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.